Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ENSG00000225213 is annotated as a novel transcript, sense intronic to RSU1, most likely representing a long non-coding RNA (lncRNA) that is transcribed from a region located within an intron of the RSU1 (Ras suppressor protein 1) gene on the sense DNA strand[1][2]. There is currently no evidence that this transcript encodes a protein, functions as a therapeutic target, or is directly related to human disease or drug interaction. Its function, relevance in physiology, and disease association are unknown, and it is not recognized in the literature as a drug target, receptor, enzyme, transporter, or other canonical therapeutic class[1][3]. The entry may be a result of automated genome annotation and is likely included as a placeholder until a function or relevance is established. No pharmacological, diagnostic, or safety data are attributed to this transcript. This target is not considered a classical or actionable drug target, and there is no established biomedical utility or clinical relevance at this time[1][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Novel transcript, sense intronic to RSU1 (ENSG00000225213).